FDA Approves Novartis TOBIÂ® Podhalerâ¿¢ For Certain Cystic Fibrosis Patients, The First And Only Dry Powder Inhaled Antibacterial In US
EAST HANOVER, N.J., March 22, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved TOBI ® Podhaler™ (tobramycin inhalation powder) 28 mg per capsule for the management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa ( Pa) bacteria in the lungs. Pa is the leading cause of loss of lung function in CF patients. It is not known if TOBI Podhaler is safe and effective in patients under six years of age, in those with lung function outside of a certain range, or in those whose lungs contain bacteria called Burkholderia cepacia.
To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/58560-novartis
TOBI Podhaler is a new, non-nebulized formulation and delivery system of tobramycin, the same active ingredient as in TOBI ® (tobramycin inhalation solution, USP) 300 mg/5 mL, which has been on the market for approximately 15 years. TOBI Podhaler is the first and only FDA-approved dry powder inhaled antibacterial for Pa in the US. It delivers tobramycin into the patient's lungs via a pocket-sized dry powder inhaler and offers better portability than TOBI, which is administered using a nebulizer. In a Phase III study, TOBI Podhaler shortened administration time for patients by approximately 70% compared to TOBI, saving about 13 hours per treatment cycle. This does not include the time saved on setting up and maintaining the nebulizer and compressor.
TOBI Podhaler does not need to be stored in a refrigerator and, unlike nebulized Pa treatments, does not require a power source to operate the delivery device. While the nebulizer used to administer TOBI must be disinfected in boiling water for 10 minutes every other treatment day, the disposable Podhaler device must only be wiped clean with a dry cloth after each use and is then replaced weekly."This is good news for the CF community," said Robert J. Beall, Ph.D., President and CEO, Cystic Fibrosis Foundation. "Managing daily CF treatments is a challenge for people with CF. TOBI Podhaler helps relieve that burden by shortening the time it takes to administer the medicine and making it easy for people with CF to take their treatment with them wherever they need to go." The new TOBI Podhaler dry powder formulation was developed using proprietary Novartis PulmoSphere™ technology. This technology enables the creation of hollow porous particles of tobramycin that can be delivered as a dry powder rather than as a nebulized solution.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV